Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TMB-H
i
Other names:
TMB | Tumor Mutational Burden
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Expression
Others
‹
TMB-L (25)
MSI-H/dMMR + TMB-H (8)
TMB-H + PD-L1 overexpression (7)
MSI-H/dMMR + TMB-L (5)
BRCA1 mutation + TMB-H (3)
KMT2D mutation + TMB-H (3)
MLL3 mutation + TMB-H (3)
MSI-H/dMMR + TMB-H + PD-L1 negative (3)
PD-L1 expression + TMB-H (3)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion + TMB-L (2)
HER-2 expression + TMB-H (2)
LRP1B mutation + TMB-H (2)
MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)
NCOR2-NTRK1 fusion + TMB-H (2)
PAPPA2 mutation + TMB-H (2)
PD-L1 expression + TMB-H + FANCA deletion (2)
STK11 mutation + TMB-H (2)
TMB-H + EGFR exon 19 deletion (2)
TMB-H + EGFR mutation (2)
TMB-H + HER-2 positive (2)
TMB-H + PD-L1 negative (2)
TMB-H + PD-L1 underexpression (2)
TMB-H + PIK3CA mutation (2)
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q) (2)
TMB-L + PD-L1 expression (2)
AHNAK2 mutation + TMB-H (1)
ALK mutation + TMB-H (1)
ARID1A mutation + TMB-H (1)
ARID1B mutation + TMB-H (1)
ASPSCR1-TFE3 fusion +TMB-H (1)
BAP1 deletion + TMB-L + PD-L1 expression (1)
BRAF mutation + TMB-H (1)
BRAF mutation + TMB-L + MSI-L/dMMR (1)
BRCA1 mutation + BRCA2 mutation + TMB-H (1)
BRCA2 mutation + TMB-H (1)
BRCA2 mutation + TMB-L (1)
CD20 positive + TMB-L (1)
CD74-ROS1 fusion + TMB-H (1)
CDKN2A mutation + TMB-H (1)
EGFR L858R + TMB-H (1)
EGFR T790M + TMB-H (1)
EGFR mutation + ALK negative + TMB-H (1)
ELF3 mutation + TMB-L + MSI-L/dMMR (1)
EML4-ALK fusion + TMB-L (1)
ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)
ERBB3 R135C + TMB-H (1)
HER-2 elevation + TMB-H (1)
HER-2 elevation + TMB-L (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HER-2 mutation + TMB-H (1)
HLA-E overexpression + TMB-L (1)
HR positive + TMB-H (1)
HR positive + TMB-L (1)
High IFNG gene signature + TMB-H (1)
IDH1 mutation + TMB-L (1)
IDH2 mutation + TMB-L (1)
KEAP1 mutation + TMB-H + PD-L1 overexpression (1)
KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H (1)
KMT2C mutation + TMB-H (1)
KRAS A146 + TMB-H (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
MAP2K1 mutation + TMB-H (1)
MAP2K2 mutation + TMB-H (1)
MET mutation + TMB-H (1)
MGA mutation + TMB-L (1)
MGAM mutation + TMB-H (1)
MLH1 methylation + MSI-H/dMMR + TMB-H (1)
MSI-H/dMMR + TMB-H + POLE mutation (1)
NCR3LG1 underexpression + TMB-L (1)
NOTCH1 mutation + TMB-L + MSI-L/dMMR (1)
NPAP1 mutation + TMB-H (1)
NTRK3 mutation + TMB-H (1)
PBRM1 mutation + TMB-H (1)
PBRM1 mutation + TMB-L + MSI-L/dMMR (1)
PD-L1 amplification + PD-L2 amplification + TMB-H (1)
PD-L1 negative + TMB-L (1)
PD-L1 negative + TMB-L + STING overexpression (1)
PD-L1 overexpression + TMB-H (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
PD-L1 overexpression + TMB-L (1)
PIK3CA E542Q + TMB-H + MSI-H/dMMR (1)
POLE E790Q + ERBB2 amplification + TMB-H (1)
POLE P286R + TMB-H (1)
POLE V1368M + ERBB3 G1271S + TNFAIP3 P714A + PRKN I69T + TSC2 G1399R + TMB-L (1)
POLE mutation + PD-L1 negative + TMB-H (1)
PTCH1 1504-1G>T + TMB-H (1)
PTPN11 mutation + TMB-H (1)
PTPRD mutation + TMB-H (1)
RECQL5 mutation + TMB-H (1)
RET amplification + TMB-H + PD-L1 expression (1)
RYR1 mutation + TMB-H (1)
SMARCA4 mutation + TMB-H (1)
SMARCB1 mutation + TMB-H (1)
STK11 deletion + TMB-H (1)
STK11 mutation + TMB-H + PD-L1 overexpression (1)
TMB-H + ALK rearrangement (1)
TMB-H + CDKN2B mutation (1)
TMB-H + DDR (1)
TMB-H + KDM6A mutation (1)
TMB-H + LDH elevation (1)
TMB-H + MLL2 mutation (1)
TMB-H + MSH6 F1088fs (1)
TMB-H + PD-L1 expression + MSI-L/dMMR (1)
TMB-H + RB1 mutation + PD-L1 underexpression (1)
TMB-H + RB1 L518fs*6 + ERCC4 R799W + TP53 C124* (1)
TMB-H + TERT promoter mutation (1)
TMB-L + ARID1A deletion + CDKN2A deletion + CDKN2B deletion + MTAP deletion + PIK3R1 N564D + NBN P81fs*23 (1)
TMB-L + LDH elevation (1)
TMB-L + PD-L1 underexpression (1)
TMB-L + RB1 mutation (1)
TP53 S12F + KRAS G12D + TMB-L (1)
TP53 mutation + FANCM mutation + TMB-H (1)
TP53 mutation + LRP1B mutation + TMB-H (1)
TP53 mutation + TMB-H + PD-L1 overexpression (1)
TPR mutation + TMB-H (1)
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)
XIRP2 mutation + TMB-H (1)
ZNF479 mutation + TMB-H (1)
HR positive + HER-2 negative + TMB-L (0)
NOTCH4 mutation + PD-L1 expression + TMB-H (0)
PIK3CA mutation + TMB-L + MSI-L/dMMR (0)
TMB-L (25)
MSI-H/dMMR + TMB-H (8)
TMB-H + PD-L1 overexpression (7)
MSI-H/dMMR + TMB-L (5)
BRCA1 mutation + TMB-H (3)
KMT2D mutation + TMB-H (3)
MLL3 mutation + TMB-H (3)
MSI-H/dMMR + TMB-H + PD-L1 negative (3)
PD-L1 expression + TMB-H (3)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion + TMB-L (2)
HER-2 expression + TMB-H (2)
LRP1B mutation + TMB-H (2)
MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)
NCOR2-NTRK1 fusion + TMB-H (2)
PAPPA2 mutation + TMB-H (2)
PD-L1 expression + TMB-H + FANCA deletion (2)
STK11 mutation + TMB-H (2)
TMB-H + EGFR exon 19 deletion (2)
TMB-H + EGFR mutation (2)
TMB-H + HER-2 positive (2)
TMB-H + PD-L1 negative (2)
TMB-H + PD-L1 underexpression (2)
TMB-H + PIK3CA mutation (2)
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q) (2)
TMB-L + PD-L1 expression (2)
AHNAK2 mutation + TMB-H (1)
ALK mutation + TMB-H (1)
ARID1A mutation + TMB-H (1)
ARID1B mutation + TMB-H (1)
ASPSCR1-TFE3 fusion +TMB-H (1)
BAP1 deletion + TMB-L + PD-L1 expression (1)
BRAF mutation + TMB-H (1)
BRAF mutation + TMB-L + MSI-L/dMMR (1)
BRCA1 mutation + BRCA2 mutation + TMB-H (1)
BRCA2 mutation + TMB-H (1)
BRCA2 mutation + TMB-L (1)
CD20 positive + TMB-L (1)
CD74-ROS1 fusion + TMB-H (1)
CDKN2A mutation + TMB-H (1)
EGFR L858R + TMB-H (1)
EGFR T790M + TMB-H (1)
EGFR mutation + ALK negative + TMB-H (1)
ELF3 mutation + TMB-L + MSI-L/dMMR (1)
EML4-ALK fusion + TMB-L (1)
ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)
ERBB3 R135C + TMB-H (1)
HER-2 elevation + TMB-H (1)
HER-2 elevation + TMB-L (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HER-2 mutation + TMB-H (1)
HLA-E overexpression + TMB-L (1)
HR positive + TMB-H (1)
HR positive + TMB-L (1)
High IFNG gene signature + TMB-H (1)
IDH1 mutation + TMB-L (1)
IDH2 mutation + TMB-L (1)
KEAP1 mutation + TMB-H + PD-L1 overexpression (1)
KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H (1)
KMT2C mutation + TMB-H (1)
KRAS A146 + TMB-H (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
MAP2K1 mutation + TMB-H (1)
MAP2K2 mutation + TMB-H (1)
MET mutation + TMB-H (1)
MGA mutation + TMB-L (1)
MGAM mutation + TMB-H (1)
MLH1 methylation + MSI-H/dMMR + TMB-H (1)
MSI-H/dMMR + TMB-H + POLE mutation (1)
NCR3LG1 underexpression + TMB-L (1)
NOTCH1 mutation + TMB-L + MSI-L/dMMR (1)
NPAP1 mutation + TMB-H (1)
NTRK3 mutation + TMB-H (1)
PBRM1 mutation + TMB-H (1)
PBRM1 mutation + TMB-L + MSI-L/dMMR (1)
PD-L1 amplification + PD-L2 amplification + TMB-H (1)
PD-L1 negative + TMB-L (1)
PD-L1 negative + TMB-L + STING overexpression (1)
PD-L1 overexpression + TMB-H (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
PD-L1 overexpression + TMB-L (1)
PIK3CA E542Q + TMB-H + MSI-H/dMMR (1)
POLE E790Q + ERBB2 amplification + TMB-H (1)
POLE P286R + TMB-H (1)
POLE V1368M + ERBB3 G1271S + TNFAIP3 P714A + PRKN I69T + TSC2 G1399R + TMB-L (1)
POLE mutation + PD-L1 negative + TMB-H (1)
PTCH1 1504-1G>T + TMB-H (1)
PTPN11 mutation + TMB-H (1)
PTPRD mutation + TMB-H (1)
RECQL5 mutation + TMB-H (1)
RET amplification + TMB-H + PD-L1 expression (1)
RYR1 mutation + TMB-H (1)
SMARCA4 mutation + TMB-H (1)
SMARCB1 mutation + TMB-H (1)
STK11 deletion + TMB-H (1)
STK11 mutation + TMB-H + PD-L1 overexpression (1)
TMB-H + ALK rearrangement (1)
TMB-H + CDKN2B mutation (1)
TMB-H + DDR (1)
TMB-H + KDM6A mutation (1)
TMB-H + LDH elevation (1)
TMB-H + MLL2 mutation (1)
TMB-H + MSH6 F1088fs (1)
TMB-H + PD-L1 expression + MSI-L/dMMR (1)
TMB-H + RB1 mutation + PD-L1 underexpression (1)
TMB-H + RB1 L518fs*6 + ERCC4 R799W + TP53 C124* (1)
TMB-H + TERT promoter mutation (1)
TMB-L + ARID1A deletion + CDKN2A deletion + CDKN2B deletion + MTAP deletion + PIK3R1 N564D + NBN P81fs*23 (1)
TMB-L + LDH elevation (1)
TMB-L + PD-L1 underexpression (1)
TMB-L + RB1 mutation (1)
TP53 S12F + KRAS G12D + TMB-L (1)
TP53 mutation + FANCM mutation + TMB-H (1)
TP53 mutation + LRP1B mutation + TMB-H (1)
TP53 mutation + TMB-H + PD-L1 overexpression (1)
TPR mutation + TMB-H (1)
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)
XIRP2 mutation + TMB-H (1)
ZNF479 mutation + TMB-H (1)
HR positive + HER-2 negative + TMB-L (0)
NOTCH4 mutation + PD-L1 expression + TMB-H (0)
PIK3CA mutation + TMB-L + MSI-L/dMMR (0)
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
(186)
News
Trials
Search handles
@ACortelliniMD
@AaronGoodman33
@Amitmahipal79
@AndreaNecchi
@AndresFCardonaZ
@ArndtVogel
@AshleySumrallMD
@AuclairDan
@AzadOncology
@BenjaminBesseMD
@BiagioMd
@BijoyTelivala
@BradMcG04
@C_Ricordel
@CarmenCalfa
@CathyEngMD
@ChrisHeery
@DocCatenacci
@DrBonillaOnc
@DrDanielHeng
@DrJNaidoo
@DrMMurphy
@DrMarkAwad
@DrR_DUNNE
@DrSteveMartin
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@FawziAbuRous
@FogacciJoao
@FordePatrick
@GeneCollector
@GeorgeSledge51
@Jaskirat__SR
@JavleMilind
@LGerratana
@MARIANOPROVENCI
@MPishvaian
@MVanMeterMD
@ManuelDomine
@Martin_AngelMD
@MichalisLiontos
@MiteshBorad
@MridulaGeorgeMD
@Myeloma_Doc
@NamBuiMD
@NicoleKuderer
@OmidHamidMD
@OncoLucus
@RachelRiechelm2
@RenoHemonc
@RielyMD
@SalemGIOncDoc
@StephenVLiu
@TaylorJ_MD
@TejasPatilMD
@TiansterZhang
@Tony_Calles
@VivekSubbiah
@aftimosp
@alantanmd
@bpiperdi
@cancerassassin1
@christine_lovly
@davidhenrymd
@dr_yakupergun
@drymtn
@hemedoc
@jamecancerdoc
@jgong15
@jonathanloree
@jsoriamd
@kevinpunie
@koshkin85
@marklewismd
@mtmdphd
@naborala
@nataliagandur
@oncoOuLungCA
@pashtoonkasi
@realbowtiedoc
@rschilsky
@sepideh_gholami
@sonpavde
@stolaney1
@teamoncology
@tompowles1
Search handles
@ACortelliniMD
@AaronGoodman33
@Amitmahipal79
@AndreaNecchi
@AndresFCardonaZ
@ArndtVogel
@AshleySumrallMD
@AuclairDan
@AzadOncology
@BenjaminBesseMD
@BiagioMd
@BijoyTelivala
@BradMcG04
@C_Ricordel
@CarmenCalfa
@CathyEngMD
@ChrisHeery
@DocCatenacci
@DrBonillaOnc
@DrDanielHeng
@DrJNaidoo
@DrMMurphy
@DrMarkAwad
@DrR_DUNNE
@DrSteveMartin
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@FawziAbuRous
@FogacciJoao
@FordePatrick
@GeneCollector
@GeorgeSledge51
@Jaskirat__SR
@JavleMilind
@LGerratana
@MARIANOPROVENCI
@MPishvaian
@MVanMeterMD
@ManuelDomine
@Martin_AngelMD
@MichalisLiontos
@MiteshBorad
@MridulaGeorgeMD
@Myeloma_Doc
@NamBuiMD
@NicoleKuderer
@OmidHamidMD
@OncoLucus
@RachelRiechelm2
@RenoHemonc
@RielyMD
@SalemGIOncDoc
@StephenVLiu
@TaylorJ_MD
@TejasPatilMD
@TiansterZhang
@Tony_Calles
@VivekSubbiah
@aftimosp
@alantanmd
@bpiperdi
@cancerassassin1
@christine_lovly
@davidhenrymd
@dr_yakupergun
@drymtn
@hemedoc
@jamecancerdoc
@jgong15
@jonathanloree
@jsoriamd
@kevinpunie
@koshkin85
@marklewismd
@mtmdphd
@naborala
@nataliagandur
@oncoOuLungCA
@pashtoonkasi
@realbowtiedoc
@rschilsky
@sepideh_gholami
@sonpavde
@stolaney1
@teamoncology
@tompowles1
Filter by
Latest
9ms
Is anyone studying SBRT + IO? Encouraged by the recent success of SBRT + atezo in early stage NSCLC- but not sure if the same biological rationale is present here (maybe in later line or high TMB NETs) @RachelRiechelm2 (@JohnEbbenMDPhD)
9 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
|
Tecentriq (atezolizumab)
9ms
🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC. Out in @NatureComms our multi-center analysis led by🌟 @alessi_joao. #biomarkers can help⬆️outcomes. @OncoAlert #LCSM (@BiagioRicciutMD)
9 months ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • TMB-H • PD-L1 overexpression
|
Imfinzi (durvalumab)
10ms
Fascinating finding!! In advanced NSCLC, high TMB (esp TMB>20) associates w durable IO benefit but PDL1 high does not? Hopeful this tool could help to guide precision IO for NSCLC. Bravo @rohit_thum and @MSKCancerCenter @DanaFarber @MDAndersonNews colleagues! (@geoff_oxnard)
10 months ago
Metastases
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
TMB-H
10ms
Hi Dr. Ocean, What is considered a high TMB for pancreatic cancer? My mother's tumor genomic testing reported 5.3m/MB & 67th percentile. Is that considered high? thank you. (@pjmorrett)
10 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
11ms
Our new article explores the limited benefits of immune checkpoint inhibitors in MSS colorectal cancer patients with high TMB. https://t.co/gv4pOVODhL. Thank you @IbrahimSahinMD1 for the opportunity and guidance. (@CharanVegivinti)
11 months ago
Clinical • Checkpoint inhibition
|
TMB (Tumor Mutational Burden)
|
TMB-H
11ms
So is this only for NSCLCs that are hot tumors with high TMB? Or also for oncogene-driven? (@LauraJBook)
11 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
11ms
Validation of high #TMB as a biomarker of benefit with single agent #IO in #pancreatic cancer Small but important cohort @UHhospitals @caseccc @doctorC369 @TedTeknosMD #asco2023 (@Amitmahipal79)
11 months ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H
11ms
You may be right that it shouldn't be rushed, but I'm kinda glad it was. For me, high TMB was the only way to Keytruda, as I'm MMRp and PD-L1 neg with mTNBC. 6th line of treatment - something had to work! 16 mos and counting! 🙂 (@DeaneDubois)
11 months ago
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
TMB-H
|
Keytruda (pembrolizumab)
11ms
So honored to mentor 🤩 @VUMCMedicineRes @VUMC_Cancer fellow @EricLanderMD . He gave a GREAT presentation on our collaboration with @NateraOncology noting: ⬆️ Her-2 and ⬆️ Her-3 in MSI-H #earlyonset #colorectal #cancer ⬆️ MSS/TMB-high w/ ⬆️ POLE MT ⬆️ ACVR2A Vs avg age onset… https://t.co/uEPgKiYtkb (@CathyEngMD)
11 months ago
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ACVR2A (Activin A Receptor Type 2A)
|
TMB-H • MSI-H/dMMR
11ms
So honored to mentor 🤩 @VUMCMedicineRes @VUMC_Cancer fellow @EricLanderMD . He gave a GREAT presentation on our collaboration with @NateraOncology noting: ⬆️ Her-2 and ⬆️ Her-3 in MSI-H/TMB high #earlyonset #colorectal #cancer ⬆️ MSS/TMB-high w/ ⬆️ POLE MT ⬆️ ACVR2A Vs avg age… https://t.co/V8XX1P4zS4 (@CathyEngMD)
11 months ago
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ACVR2A (Activin A Receptor Type 2A)
|
TMB-H • MSI-H/dMMR
12ms
Amazing molecular tumor #MTB board in #GUcsm with @FoundationATCG Two ✌️ interesting cases ➡️ Penile carcinoma 🧬high TMB & BRCA & HER2 amplification....What to do?? By @fedelosco ➡ Prostate cancer 🧬HRR mutation in MRE11A. Does iPARP work?. By me @fundacion_FUCA @IAF_Fleming (@Martin_AngelMD)
12 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset) • MRE11A (MRE11 homolog, double strand break repair nuclease)
|
TMB-H • HER-2 amplification • MRE11A mutation
12ms
Great talk by Dr. Loibl on ICI in early stg TNBC 📌 low TMB tumors had greater benefit w Durvalumab compared to high TMB 📌 do we need anthracylc in TNBC in the era of IO TX ➡️ geparBOOG study ongoing 📌 ?role of adjuvant ICI s/p neoadj ICI. ➡️GeparDouze #ESMOBreast23 @OncoAlert (@MridulaGeorgeMD)
12 months ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H • TMB-L
|
Imfinzi (durvalumab)
12ms
To add to this excellent thread, not all POLE mutations = high #TMB as you may notice on #NGS report - most pathogenic #POLE mutations that lead to ultra-mutated #crcsm #MSS phenotype cluster around the active DNA-binding sites of the exonuclease proofreading domain (@jgong15)
12 months ago
Next-generation sequencing
|
TMB (Tumor Mutational Burden) • POLE (DNA Polymerase Epsilon)
|
TMB-H • POLE mutation
12ms
💫BRCA2 vs ATM mutations in metastatic prostate cancer: Divergent molecular features & clinical outcomes 💫 🔬 BRCA2 mutations linked to higher mutational burden & genomic instability 👨⚕️ Patients with BRCA2 mutations had better response to PARP inhibitors 💊 ATM mutations… https://t.co/0szeSSwAoc (@nataliagandur)
12 months ago
Clinical • Clinical data • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase)
|
BRCA2 mutation • TMB-H • ATM mutation • BRCA2 mutation + ATM mutation
12ms
💫BRCA2 vs ATM mutations in metastatic prostate cancer: Divergent molecular features & clinical outcomes 💫 🔬 BRCA2 mutations linked to higher mutational burden & genomic instability 👨⚕️ Patients with BRCA2 mutations had better response to PARP inhibitors 💊 ATM mutations… https://t.co/fD1GFRle4v (@nataliagandur)
12 months ago
Clinical • Clinical data • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase)
|
BRCA2 mutation • TMB-H • ATM mutation • BRCA2 mutation + ATM mutation
12ms
TMB-h in #NETCancer predicts response to immunotherapy? Favorable response to immunotherapy in TMB-h G3 #NETCancer doi: 10.1002/cac2.12114 doi: 10.1200/PO.22.00009 (@RachelRiechelm2)
12 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
12ms
We really don’t know. … we have seen high TMB for pts whose #NETCancer harbor pathogenic Germline variants in MUTHY @gitorrezan (@RachelRiechelm2)
12 months ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Treatment for KRAS G12C Mutated NSCLC with High Tumor Mutational Burden ... https://t.co/qGKggDWoZg via @YouTube n this video Drs. @IbiayiMD, Kathryn Arbour, and @NIVokes discuss treatment options for patients who have KRAS G12C Mutated NSCLC and a high tumor mutational burden. (@cancerGRACE)
1 year ago
Clinical • Video • Tumor mutational burden
|
KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden)
|
KRAS mutation • TMB-H • KRAS G12C • KRAS G12
1year
2/8 We identified 562 deleterious ATM mutations in 9.7% (503/5172) of NSCLC samples. ATM mutations were associated with high TMB, increased PD-L1 expression and were enriched in KRAS, STK11, and ARID2 co-mutations. TP53 and EGFR mutations were enriched in ATM wild-type NSCLCs. (@BiagioMd)
1 year ago
IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11) • ARID2 (AT-Rich Interaction Domain 2)
|
PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • TMB-H • ATM mutation • STK11 mutation • KRAS mutation + STK11 mutation + TP53 mutation • KRAS expression
1year
Penultimate day at #AACR2023! Take some time to stop by the posters and see our work on Pan-cancer analysis of XPO1 R749Q mutations reveals association with high TMB and therapeutic resistance #4253 (section 31, board 2) #CRCsm #GYNCsm #Cancer #CancerResearch (@TaylorJ_MD)
1 year ago
IO biomarker • Pan tumor
|
TMB (Tumor Mutational Burden) • XPO1 (Exportin 1)
|
TMB-H • XPO1 R749Q • XPO1 mutation
1year
Desmoplastic melanomas have lot of UV damage and high TMB , not a big surprise .. (@RenoHemonc)
1 year ago
TMB (Tumor Mutational Burden)
|
TMB-H
1year
#ctDNA profiling of bTMB and copy number burden (bCNB) can predict poor outcomes in patients with #metastatic #BreastCancer treated with ET and CDK4/6i. Dominant APOBEC signatures were detected at baseline in cases with high bTMB. #bcsm #PrecisionMedicine https://t.co/W2sYZ1ij4Q (@LGerratana)
1 year ago
Clinical • Tumor mutational burden • Circulating tumor DNA • Metastases
|
TMB (Tumor Mutational Burden) • CDK4 (Cyclin-dependent kinase 4)
|
TMB-H
1year
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden https://t.co/cxIhSqikK1 (@AndresFCardonaZ)
1 year ago
Clinical • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden)
|
TMB-H
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
1year
🔥Tumor mutational burden as a biomarker in patients with MSI #colorectalcancer treated with immune checkpoint inhibitors @OncologyAdvance https://t.co/YWWhyJ7ExW 🔎🇮🇹RWD 110 pts 👉low TMB -> cold tumors -> poor outcome 👉high TMB -> max benefit with anti-PD-1/CTLA-4 @myESMO… https://t.co/GPuu1CFTem (@ArndtVogel)
1 year ago
Clinical • Checkpoint inhibition • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
TMB-H • TMB-L
1year
As a Sg 4 NSCLC BRAF v600e dx 8/2019, so much to appreciate here, esp the patient section! I'm back on pembro after a year's break followed by progression. Appear to be responding well (PD-L1 neg but high TMB). 🤍how pt emphasizes hope for others. #includeus (@AlysonH70982913)
1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
|
BRAF V600E • TMB-H
|
Keytruda (pembrolizumab)
1year
He’s a 10 but he’s a misleading tumor mutational burden (@HJLenz59 argues for a MUCH higher TMB threshold for response prediction to IO in mCRC) @CMECedarsSinai @DrHendifar @jgong15 @PamelaKunzMD #crcsm (@marklewismd)
1 year ago
Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Not all TMB-high are created equal & predict for #immunotherapy efficacy. In GI cancers with MSS & TMB-high, mutations in SMAD2, MTOR, NFE2L2, RB1, KEAP1, TERT, & RASA1 were associated with suppressed tumor immune environment. https://t.co/YtBonLmOZs (@jsoriamd)
1 year ago
Clinical • IO biomarker
|
TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • mTOR (Mechanistic target of rapamycin kinase) • RASA1 (RAS P21 Protein Activator 1) • SMAD2 (SMAD Family Member 2)
|
TMB-H • MTOR mutation
1year
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study https://t.co/bu1wdy9Ags (@JavleMilind)
1 year ago
Retrospective data • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study @TheLancetOncol https://t.co/6CWo26E0SX (@VivekSubbiah)
1 year ago
Retrospective data • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Discussion across GU malignancies to start day at #GU23 Biomarkers of response to Enfortumab Vedotin in UC, cabo/nivo in RCC, updated analysis of nivo/ipi of CRPC - high TMB not predictive of benefit and new clinical risk stratification for relapse in stage 1 seminoma @OncLive (@BradMcG04)
1 year ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Padcev (enfortumab vedotin-ejfv)
1year
The Oral abstracts have started #GU23! Biomarkers for urothelial cancer! High TMB good in EV treated patients. This was a great talk. @OncoAlert @ASCOPost (@DrDanielHeng)
1 year ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
UNITE: Biomarkers for EV in pts with advanced UC #GU23 @urotoday 📌 n=170 📌 Longer OS with high TMB 📌 Shorter PFS for CDKN2A, CDKN2B or MTAP alterations (@zklaassen_md)
1 year ago
Clinical • Metastases
|
TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
TMB-H
1year
Please join us in Oral Testis/Penile abstract session #GU23 we will present features of #penilecancer with high TMB, including the original germline mutation frequencies @SpiessPhilippe @FoundationATCG @MyUniSR @urotoday @ASCO @GTumors (@AndreaNecchi)
1 year ago
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Excellent perspective on issue we face in our MDT on pts w/“high” & MSS…more than meets the 👁️ as we delve deeper into NGS. Mutational analysis of microsatellite-stable GI cancer with high tumour mutational burden: a retrospective cohort study https://t.co/IZ5c2ObKSs (@drymtn)
1 year ago
Retrospective data • Next-generation sequencing • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
🔥Mutational analysis of MSS GI cancer with TMBhigh @TheLancetOncol https://t.co/4RWhL2SfYF ✅48606 pts CARIS 👉MSS/TMB-H 3.3% 👉Distinct genomic profile relevant for IO 👉mTMB gene signature for IO efficacy 👉 CCND1, FGF, HER2 CNV ⬆️ -> combination💊? @myESMO @OncoAlert (@ArndtVogel)
1 year ago
Clinical • Gene Signature
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CCND1 (Cyclin D1) • FGF (Fibroblast Growth Factor)
|
TMB-H
over1year
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study - The Lancet Oncology https://t.co/BKmyRWsyrR (@jonathanloree)
over 1 year ago
Retrospective data • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
over1year
No activity of anti-PD-1 monoRx in mCRPC in unselected pts, no enrichment for high-TMB or MSI-H, highly active control arm....the odds were always stacked against this trial sadly. Another negative immunotherapy trial in #ProstateCancer ...... (@AzadOncology)
over 1 year ago
Clinical
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR
over1year
Not surprising but a disappointment. Still, make sure to test all metastatic prostate cancer patients for MSI-H and TMB-H as pembrolizumab is active and is standard care in prostate cancers with these rare phenotypes (~5% of our patients). (@DSolit)
over 1 year ago
Clinical • Metastases
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR
|
Keytruda (pembrolizumab)
over1year
Mutational analysis of MSS GI cancer with high TMB: 💥Not all mutations related to TMB-H can enhance antitumour immune response 💥Although TMB is low, some mutations increase the immune response ❗Attention should be paid to the function of mutations https://t.co/nGPF2yLvUb (@dr_yakupergun)
over 1 year ago
TMB (Tumor Mutational Burden)
|
TMB-H
over1year
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study - The Lancet Oncology https://t.co/JirJeZzp1E (@ChrisHeery)
over 1 year ago
Retrospective data • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
over1year
Happening now @ASCO #GI23 poster session. @AnwaarSaeed3 presents a study of colorectal patients with Microsatellite Stable disease with high Tumor Mutation Burden (TMB). Level 1 West Hall Poster #N11 (@UPMCHillmanCC)
over 1 year ago
Clinical • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
over1year
Check out our poster on high TMB in MSS CRC at #GI23 @ASCO love this collaborative group! @AnwaarSaeed3 @cancerassassin1 @mgfakih @jonathanloree @skopetz @MayCho_MD @NorthwellHealth @CSHL @MDAndersonNews @CCAlliance @FightCRC @UPMCHillmanCC (@sepideh_gholami)
over 1 year ago
TMB (Tumor Mutational Burden)
|
TMB-H
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login